Discover
Taltz (ixekizumab) / Eli LillyEfficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis (EADV 2019) - Sep 24, 2019 - Abstract #D3T01.1B; Pres time: Oct 12, 2019; 08:45 AM - 09:00 AM; Location: Hall 10 Dalí; No abstract available.Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimSkyrizi sales projection: $250M in 2019, $850M in 2020 and $3B in 2024 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 491; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Taltz (ixekizumab) / Eli LillyTaltz sales projection: $1.38B in 2019, $1.93B in 2020 and $3.1B in 2024 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 484; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Sales projectionOtezla (apremilast) / AmgenOtezla sales projection: $3B in 2024 (Cowen & Co) - Sep 26, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2914; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Stelara (ustekinumab) / J&JStelara WW sales projection: $9B in 2024 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 479; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Cosentyx (secukinumab) / NovartisCosentyx sales projection: $3.27B in 2019, $3.59B in 2020 and $5.1B in 2024 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 487; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Sales projectionStelara (ustekinumab) / J&JStelara WW sales projection: $6.2B in 2019, $7B in 2020 and $10B in 2024 (Cowen & Co) - Sep 26, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2917; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Tremfya (guselkumab) / J&JTremfya WW sales projection: >$2.5B in 2024 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 481; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimNow comes a new effective medicine for psoriasis [Google Translation] - Sep 24, 2019 - "Decision forums have given thumbs to Skyrizi - AbbVie's innovative drug for plaque psoriasis. - Skyrizi is cost-effective and has a well-documented effect. We are therefore pleased to be able to offer patients this drug, says the head of the Decision Forum Stig A. Slørdahl....We look forward to seeing more of the two-year data from the IMMhance study at the World Congress of Dermatology in June 2020..."
